Efficacy News and Research

RSS
People with hybrid immunity are the most protected against severe COVID-19 and reinfection

People with hybrid immunity are the most protected against severe COVID-19 and reinfection

Advantages and challenges of using interstitial fluid for disease diagnosis, health monitoring

Advantages and challenges of using interstitial fluid for disease diagnosis, health monitoring

New trial evaluates Omicron BA.1–adapted BNT162b2 vaccine in older adults

New trial evaluates Omicron BA.1–adapted BNT162b2 vaccine in older adults

WHO to launch council to accelerate the development of TB vaccine

WHO to launch council to accelerate the development of TB vaccine

Researchers create the first 'living medicine' to treat drug-resistant lung infections

Researchers create the first 'living medicine' to treat drug-resistant lung infections

Wistar scientists receive $397,663 to explore the ability of natural killer cells to kill HIV-infected cells

Wistar scientists receive $397,663 to explore the ability of natural killer cells to kill HIV-infected cells

Exploring the infectivity, transmissibility, and immunological resistance characteristics of SARS-CoV-2 Omicron XBB.1.5 strain

Exploring the infectivity, transmissibility, and immunological resistance characteristics of SARS-CoV-2 Omicron XBB.1.5 strain

Researchers find that study results converge on a consistent relationship between antibody levels and protection from COVID-19

Researchers find that study results converge on a consistent relationship between antibody levels and protection from COVID-19

Study elucidates the potential role of STRO-001 in B-cell non-Hodgkin lymphoma

Study elucidates the potential role of STRO-001 in B-cell non-Hodgkin lymphoma

Genotyping technology may help increase the number of kidney transplantations and reduce wait times

Genotyping technology may help increase the number of kidney transplantations and reduce wait times

The efficacy of low-dose fluvoxamine compared with placebo for treating mild to moderate COVID-19 in the US

The efficacy of low-dose fluvoxamine compared with placebo for treating mild to moderate COVID-19 in the US

What older Americans need to know about taking Paxlovid

What older Americans need to know about taking Paxlovid

Researchers examine impact of gamification on the effectiveness of digital health interventions

Researchers examine impact of gamification on the effectiveness of digital health interventions

Intelligent fire suits and masks can help firefighters effectively avoid danger in future

Intelligent fire suits and masks can help firefighters effectively avoid danger in future

Heart Foundation calls for regulatory actions to better protect Australians from e-cigarettes

Heart Foundation calls for regulatory actions to better protect Australians from e-cigarettes

Preclinical study shows the therapeutic value of kinetin against SARS-CoV-2

Preclinical study shows the therapeutic value of kinetin against SARS-CoV-2

Researchers report that vectored expression of a high-affinity ACE2 microbody protein establishes a high degree of protection from SARS-CoV-2

Researchers report that vectored expression of a high-affinity ACE2 microbody protein establishes a high degree of protection from SARS-CoV-2

Intranasal mRNA-lipid nanoparticle vaccines elicit significant protection against SARS-CoV-2 in hamsters

Intranasal mRNA-lipid nanoparticle vaccines elicit significant protection against SARS-CoV-2 in hamsters

COVID-19 convalescent plasma transfusions significantly reduced mortality rates among hospitalized SARS-CoV-2 patients

COVID-19 convalescent plasma transfusions significantly reduced mortality rates among hospitalized SARS-CoV-2 patients

What is the efficacy of the COVID-19 second booster versus the first booster with prior COVID-19 infections?

What is the efficacy of the COVID-19 second booster versus the first booster with prior COVID-19 infections?

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.